Skip to main content

Table 1 Characteristics of patients with six months follow-up before and six months after the index date included in interrupted time series analyses analysis (n = 27657a)

From: Cohort study of medical cannabis authorization and motor vehicle crash-related healthcare visits in 2014–2017 in Ontario, Canada

Characteristic Unauthorized for medical cannabis
(N = 17,732)
Authorized for medical cannabis
(N = 9925)
p-value
Age
  < 21 143 (0.8%) 78 (0.8%) 0.9957
 21 to 30 1855 (10.5%) 1063 (10.7%)
 31 to 40 3553 (20.0%) 1993 (20.1%)
 41 to 50 3876 (21.9%) 2135 (21.5%)
  to 60 4545 (25.6%) 2562 (25.8%)
 61 to 70 2527 (14.3%) 1414 (14.3%)
 71 to 80 891 (5.0%) 491 (5.0%)
  > 80 342 (1.9%) 189 (1.9%)
Sex
 Female 8054 (45.4%) 4462 (45.0%) 0.4576
 Male 9678 (54.6%) 5463 (55.0%)
Nearest Census based neighborhood income quintile
 1 3963 (22.4%) 2212 (22.3%) 0.9939
 2 3785 (21.4%) 2103 (21.2%)
 3 3347 (18.9%) 1893 (19.1%)
 4 3490 (19.7%) 1959 (19.7%)
 5 3147 (17.8%) 1758 (17.7%)
Rural 1891 (10.7%) 797 (8.0%) < 0.0001
Diagnosis codes
 Diabetes 1945 (11.0%) 1132 (11.4%) 0.2680
 Congestive heart failure 97 (0.6%) 64 (0.6%) 0.3051
 COPD 2028 (11.4%) 1187 (12.0%) 0.1933
 Asthma 3438 (19.4%) 1965 (19.8%) 0.4096
 Cancer 1250 (7.1%) 726 (7.3%) 0.4110
 Musculoskeletal issues 7791 (43.9%) 4377 (44.1%) 0.7931
 Neurologic disorders 2564 (14.5%) 1515 (15.3%) 0.0702
 Pain 401 (2.3%) 280 (2.8%) 0.0040
 Behavioural issues 3313 (18.7%) 1929 (19.4%) 0.1259
 Fatigue 188 (1.1%) 139 (1.4%) 0.0120
 Metabolic disease 2132 (12.0%) 1286 (13%) 0.0236
 Anxiety at baseline 4313 (24.3%) 4867 (49.0%) < 0.0001
  1. a29153 adult patients were identified and subsequently linked to the administrative databases of the Ontario Ministry of Health providing up to at least 6 months of longitudinal follow-up data following the initial medical cannabis consultation. All data was released as de-identified data
  2. COPD Chronic obstructive pulmonary disease